Gene-Hormone Therapy Interaction and Fracture Risk in Postmenopausal Women

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2017 Mar 22

PMID 28324062

Citations 4

Authors

Youjin Wang

Jean Wactawski-Wende

Lara E Sucheston-Campbell

Leah Preus

Kathleen M Hovey

Jing Nie

Rebecca D Jackson

Samuel K Handelman

Rami Nassir

Carolyn J Crandall

Heather M Ochs-Balcom

Affiliations

Soon will be listed here.

Abstract

Context: Evidence supports a protective effect of menopausal hormone therapy (HT) on bone. However, whether genetic susceptibility modifies the association of HT and fracture risk is not sufficiently explored.

Objective: The objective was to test an interaction between genetic susceptibility and HT on fracture risk.

Design: We constructed two weighted genetic risk scores (GRSs) based on 16 fracture-associated variants (Fx-GRSs) and 50 bone mineral density variants (BMD-GRSs). We used Cox regression to estimate the main effects of GRSs and their interactions with HT on fracture risk. We estimated the relative excess risk due to interaction (RERI) as a measure of additive interaction. We also used the case-only approach to test for a multiplicative interaction.

Setting: Forty US clinical centers.

Participants: A total of 9922 genotyped white postmenopausal women (age, 50 to 79) from the Women's Health Initiative HT randomized trials.

Main Outcome Measures: Adjudicated fracture incidence.

Results: Both GRSs were associated with fracture risk per 1-unit increment in GRS (hazard ratio, 1.04 [95% confidence interval, 1.02 to 1.06] for Fx-GRS and hazard ratio, 1.03 [95% confidence interval,1.02-1.04] for BMD-GRS). We found no evidence for multiplicative interaction for either of the GRS. However, we observed a substantial additive interaction, where the highest quartile of both GRSs and randomization to placebo have excess fracture risk: Fx-GRS P for RERI = 0.047, BMD-GRS P for RERI = 0.046.

Conclusions: These results suggest that HT reduces fracture risk in postmenopausal women, especially in those at highest genetic risk of fracture and low BMD.

Citing Articles

Modulation of Bone Mineral Density and Its Response to Menopausal Hormone Therapy according to the Apolipoprotein E Genotype in Postmenopausal Korean Women.

Seo J, Yoon S, Lim H, Shin W, Kim W, Min Y J Menopausal Med. 2024; 30(1):37-43.

PMID: 38714492 PMC: 11103072. DOI: 10.6118/jmm.23033.

Applying polygenic risk score methods to pharmacogenomics GWAS: challenges and opportunities.

Zhai S, Mehrotra D, Shen J Brief Bioinform. 2023; 25(1).

PMID: 38152980 PMC: 10782924. DOI: 10.1093/bib/bbad470.

Is Gonadal Therapy a Promoter of Breast Cancer? Incidence of Breast Cancer in a Cohort of Survivors of Oncological Diseases Treated with Gonadal Steroids.

Dias D, Esteves S, Andrade S, Maciel J, Cavaco D, Simoes-Pereira J Case Rep Oncol. 2020; 13(1):347-357.

PMID: 32308603 PMC: 7154255. DOI: 10.1159/000506395.

Interval breast cancer is associated with other types of tumors.

Grassmann F, He W, Eriksson M, Gabrielson M, Hall P, Czene K Nat Commun. 2019; 10(1):4648.

PMID: 31641120 PMC: 6805891. DOI: 10.1038/s41467-019-12652-1.

References

Crandall C, Yildiz V, Wactawski-Wende J, Johnson K, Chen Z, Going S . Postmenopausal weight change and incidence of fracture: post hoc findings from Women's Health Initiative Observational Study and Clinical Trials. BMJ. 2015; 350:h25. PMC: 6168976. DOI: 10.1136/bmj.h25. View

Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K . Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007; 130(5):811-23. DOI: 10.1016/j.cell.2007.07.025. View

Kanis J, Johnell O, Oden A, Johansson H, McCloskey E . FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19(4):385-97. PMC: 2267485. DOI: 10.1007/s00198-007-0543-5. View

Laurie C, Doheny K, Mirel D, Pugh E, Bierut L, Bhangale T . Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol. 2010; 34(6):591-602. PMC: 3061487. DOI: 10.1002/gepi.20516. View

Cauley J, Robbins J, Chen Z, Cummings S, Jackson R, LaCroix A . Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003; 290(13):1729-38. DOI: 10.1001/jama.290.13.1729. View

. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998; 19(1):61-109. DOI: 10.1016/s0197-2456(97)00078-0. View

Stefanick M, Cochrane B, Hsia J, Barad D, Liu J, Johnson S . The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003; 13(9 Suppl):S78-86. DOI: 10.1016/s1047-2797(03)00045-0. View

Manolagas S . Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000; 21(2):115-37. DOI: 10.1210/edrv.21.2.0395. View

Karasik D, Rivadeneira F, Johnson M . The genetics of bone mass and susceptibility to bone diseases. Nat Rev Rheumatol. 2016; 12(6):323-34. DOI: 10.1038/nrrheum.2016.48. View

10.

Woolf A, Akesson K . Preventing fractures in elderly people. BMJ. 2003; 327(7406):89-95. PMC: 1126451. DOI: 10.1136/bmj.327.7406.89. View

11.

Andrew T, Antioniades L, Scurrah K, MacGregor A, Spector T . Risk of wrist fracture in women is heritable and is influenced by genes that are largely independent of those influencing BMD. J Bone Miner Res. 2004; 20(1):67-74. DOI: 10.1359/JBMR.041015. View

12.

Stone K, Seeley D, Lui L, Cauley J, Ensrud K, Browner W . BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003; 18(11):1947-54. DOI: 10.1359/jbmr.2003.18.11.1947. View

13.

Hosmer D, Lemeshow S . Confidence interval estimation of interaction. Epidemiology. 1992; 3(5):452-6. DOI: 10.1097/00001648-199209000-00012. View

14.

Manolagas S, OBrien C, Almeida M . The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013; 9(12):699-712. PMC: 3971652. DOI: 10.1038/nrendo.2013.179. View

15.

Ho-Le T, Center J, Eisman J, Nguyen H, Nguyen T . Prediction of Bone Mineral Density and Fragility Fracture by Genetic Profiling. J Bone Miner Res. 2016; 32(2):285-293. DOI: 10.1002/jbmr.2998. View

16.

Michaelsson K, Melhus H, Ferm H, Ahlbom A, Pedersen N . Genetic liability to fractures in the elderly. Arch Intern Med. 2005; 165(16):1825-30. DOI: 10.1001/archinte.165.16.1825. View

17.

Cornelis M, Agrawal A, Cole J, Hansel N, Barnes K, Beaty T . The Gene, Environment Association Studies consortium (GENEVA): maximizing the knowledge obtained from GWAS by collaboration across studies of multiple conditions. Genet Epidemiol. 2010; 34(4):364-72. PMC: 2860056. DOI: 10.1002/gepi.20492. View

18.

Jackson R, Wactawski-Wende J, LaCroix A, Pettinger M, Yood R, Watts N . Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res. 2006; 21(6):817-28. DOI: 10.1359/jbmr.060312. View

19.

Browning B, Browning S . A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet. 2009; 84(2):210-23. PMC: 2668004. DOI: 10.1016/j.ajhg.2009.01.005. View

20.

Jackson R, LaCroix A, Gass M, Wallace R, Robbins J, Lewis C . Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006; 354(7):669-83. DOI: 10.1056/NEJMoa055218. View